CAMRF:OTC-Camurus AB (publ) (USD)

COMMON STOCK | |

Last Closing

USD 57

Change

0.00 (0.00)%

Market Cap

USD 0.45B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Camurus AB (publ), a research-based pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Sweden, North America, and internationally. The company's development pipeline contains product candidates for the treatment of cancer and the side effects of cancer treatment, endocrine diseases, pain, opioid dependence, and addiction. It also offers episil oral liquid, a medical device for the treatment of inflammatory and painful conditions. The company was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB (publ) is a subsidiary of Sandberg Development AB.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
PSZKF Powszechna Kasa Oszczednosci B..

N/A

USD 13.13B
SHZHY Shenzhou International Group H..

-0.06 (-0.76%)

USD 11.92B
ELPQF El Puerto de Liverpool S.A.B. ..

N/A

USD 10.80B
PSHZF Pershing Square Holdings Ltd

+0.19 (+0.41%)

USD 10.03B
IDKOF Idemitsu Kosan Co.Ltd

N/A

USD 9.59B
EFGSF Eiffage SA

N/A

USD 8.15B
SKSUF Sekisui Chemical Co. Ltd

N/A

USD 7.67B
AZRGF Azrieli Group Ltd

N/A

USD 7.63B
RUMOF Rumo S.A

N/A

USD 7.02B
DFKCY Daifuku Co. Ltd

+0.07 (+0.74%)

USD 6.64B

ETFs Containing CAMRF

ZJO:CA 4.39 % 0.60 %

N/A

N/A
GASX 4.34 % 1.01 %

N/A

N/A
SCAP Series Portfolios Trust 2.21 % 0.90 %

+0.12 (+0%)

N/A
GASL 1.55 % 1.19 %

N/A

N/A
IWN iShares Russell 2000 Valu.. 0.00 % 0.00 %

+0.14 (+0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 161.35% N/A N/A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 161.35% N/A N/A 88% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 42.35% N/A N/A 74% C
Dividend Return 42.35% N/A N/A 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.70% N/A N/A 49% F
Risk Adjusted Return 78.87% N/A N/A 96% N/A
Market Capitalization 0.45B N/A N/A 68% D+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.